MedTrace Logo

Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal

NCT03696680 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-02-11

No results posted yet for this study

Summary

This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases

Conditions

  • Hemorrhagic Brain Metastases

Interventions

RADIATION

FSRT Stereotactic radiation therapy

For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days

Sponsors & Collaborators

  • ANOCEF/IGCNO

    collaborator UNKNOWN

  • Groupement Interrégional de Recherche Clinique et d'Innovation

    collaborator OTHER

  • Centre Francois Baclesse

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-16
Primary Completion
2027-06-30
Completion
2028-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03696680 on ClinicalTrials.gov